Funded Grants

The main aim of this project is to examine the efficacy of the non-pharmacological intervention of lower body negative pressure (LBNP) with head up tilt on cerebral blood flow and concussion symptoms during exercise in individuals with persisting symptoms.

The LINGO-1 protein is strongly associated with Alzheimer’s disease and is a novel drug target.

By the time a person receives a diagnosis of Alzheimer’s disease (AD) dementia, brain atrophy is such that memory impairments are irreversible.

Neurodegenerative conditions such as Alzheimer’s and Parkinson’s disease profoundly affect aspects of cognition including memory

Injuries and diseases of the nervous system have devastating effects.

Patients with neurological disease are understandably frustrated by the lack of meaningful pharmacological treatments for even comparatively common pathologies such as Parkinson’s Disease.

Mood disorders such as depression and bipolar disorder affect over 350 million people around the world.

Brain-based disorders such as epilepsy, stroke, acquired brain injury, and Parkinson’s Disease impact tens of thousands of Canadians each year.